Recombinant Human EPO Protein, Active, Low Endotoxin
Description
Product Overview
| Product Name | Recombinant Human EPO Protein |
| Target Symbol | EPO |
| Alternative Names | Erythropoietin, Epoetin, EP, ECYT5, MVCD2, DBAL |
| Accession Number | P01588 |
| Expression System | HEK293 Cell |
| Molecular Weight | 21 kDa (monomer, predicted), 30-45 kDa (observed) |
| Sequence | Ala28-Arg193 |
| Purity | >98% by SDS-PAGE and quantitative densitometry by Coomassie® Blue staining |
| Activity | Determined by a cell proliferation assay using TF-1 cells. The ED50 for this effect is typically <0.5 ng/mL. |
| Formulation | Lyophilized from sterile PBS with Trehalose, pH 7.4 |
| Endotoxin Level | <0.001 EU per 1 µg of the protein as determined by the LAL method |
| Shipping | Shipped at ambient temperature. |
| Stability & Storage | 12 months from date of receipt at -20°C to -70°C, lyophilized powder. 3 months at -20°C to -70°C under sterile conditions after reconstitution. Avoid repeated freeze-thaw cycles. |
| Reconstitution | Reconstitute at 100 μg/mL in PBS. Optionally, use PBS with 0.1% BSA. |
| Target Function | EPO is the primary regulator of red blood cell production. It acts as a growth factor that promotes erythroid differentiation, stimulates red blood cell maturation, and initiates hemoglobin synthesis. It acts by binding to the Erythropoietin Receptor (EPOR) on target cells, activating signalling pathways (like JAK2/STAT5) that prevent apoptosis (cell death) of erythroid progenitors. |
| Tissue Specificity | The kidneys—specifically renal interstitial fibroblasts—are the primary source of this protein, while the liver serves as a secondary source, especially during fetal development. Despite the liver showing the highest mRNA expression, the functional protein is released into the bloodstream to act upon the bone marrow. |
| Cellular Localization | Secreted protein |
| Involvement In Disease | Low levels of erythropoietin (EPO) lead to anemia, especially in chronic kidney disease, while excessive production causes polycythemia by creating too many red blood cells. Abnormal EPO signaling is also linked to erythroleukemia, familial erythrocytosis, and potential tumor growth in glioma or cervical cancer. To treat anemia related to kidney disease, chemotherapy, or HIV, doctors use recombinant human EPO versions like epoetin alfa, beta, delta, and omega. |
Intended use
Research Use Only
Specifications
| Product information | |
|---|---|
| Catalog number | BEP-0001UL |
| Size | 100ug |
Need a different construct, tag or scale?
Our custom recombinant protein production service covers gene synthesis, expression in E. coli, yeast, insect and mammalian cells, purification and QC, for Non-GMP research or GMP manufacturing.